Specialties – Page 36

Harnessing AI: LLM-Based Conversational Agents Reduce Depression and Anxiety Among Young Adults in Short Video App Trial

By MedXY 09/14/2025

A 28-day RCT demonstrates that a conversational AI trained on a large language model effectively reduces mild depression and anxiety symptoms in young adults through dialog interventions integrated in short video apps.

AI Gastroenterology Specialties

AI-Assisted Optical Diagnosis in Colonoscopy: Ensuring Safety While Reducing Unnecessary Polypectomies

By MedXY 09/14/2025

A randomized trial demonstrates that leaving small non-neoplastic colorectal polyps in situ with AI-assisted optical diagnosis is as safe and effective as systematic removal, supporting less invasive colonoscopy strategies.

Family Medicine & Nutrition news Specialties

Lower Your Blood Pressure by 8 mmHg in Just 10 Minutes a Day: The Power of Isometric Exercises

By MedXY 09/14/2025

Isometric exercises, a form of static muscle engagement, can lower blood pressure as effectively as some medications, offering a simple, drug-free way to protect your heart and vessels.

Dentistry Family Medicine & Nutrition Specialties

The Hidden Threat in Your Mouth: How Oral Bacteria Can Trigger Heart Attacks

By MedXY 09/14/2025

New research reveals that common oral bacteria, particularly Viridans streptococci, can infiltrate arterial plaques, increasing the risk of heart attacks by triggering inflammation and plaque rupture.

General Surgery Specialties

Oral Corticosteroids Fail to Improve Recovery in Vocal Fold Paralysis After Thyroid Surgery: Insights from a Randomized Clinical Trial

By MedXY 09/13/2025

A randomized trial shows that a 7-day course of oral corticosteroids does not enhance vocal fold remobilization or voice quality in unilateral vocal fold paralysis following thyroid or parathyroid surgery, underscoring the continued importance of speech therapy.

Clinical Updates Gastroenterology Oncology Public Health Specialties

Optimizing Colorectal Cancer Screening Outreach for Adults Aged 45-49: Insights From a Large-Scale Randomized Trial

By MedXY 09/13/2025

A large UCLA Health randomized clinical trial found that usual care via mailed FIT outreach outperformed active choice strategies in colorectal cancer screening uptake among adults aged 45 to 49 years, highlighting the challenges in engaging younger populations in screening programs.

Clinical Updates Psychiatry

Accelerating Depression Recovery: The Impact of Measurement-Based Care in Pakistan’s Low-Resource Settings

By MedXY 09/13/2025

A randomized clinical trial in Pakistan demonstrates that measurement-based care accelerates antidepressant treatment response and remission in major depressive disorder compared to standard care, underscoring its potential in low-resource settings.

Clinical Updates news Psychiatry Specialties

Personalized High-Definition Transcranial Direct Current Stimulation: A Promising Rapid Intervention for Moderate to Severe Depression

By MedXY 09/13/2025

A randomized clinical trial demonstrates that personalized high-definition transcranial direct current stimulation (HD-tDCS) significantly improves mood in patients with moderate to severe depression, showing faster and comparable effect sizes to conventional therapies and also reducing anxiety symptoms.

Cardiology General Surgery news Specialties

Unexpected Risks of Postoperative 20% Albumin Infusion in High-Risk Cardiac Surgery Patients: Insights from the ALBICS AKI Trial

By MedXY 09/13/2025

The ALBICS AKI trial reveals that postoperative infusion of 20% albumin increases acute kidney injury risk in high-risk cardiac surgery patients, challenging prior assumptions about albumin's nephroprotective role in this setting.

Cardiology Specialties

Finerenone Efficacy and Safety Across Frailty Levels in Heart Failure: Insights from the FINEARTS-HF Trial

By MedXY 09/13/2025

This analysis of the FINEARTS-HF trial reveals that finerenone reduces cardiovascular death and heart failure worsening regardless of frailty status, without increasing adverse events, supporting its use in frail patients with HFmrEF or HFpEF.

Cardiology Clinical Updates Family Medicine & Nutrition Radiology Specialties

CT Angiography Enhances Lifestyle and Prevention Uptake in Cardiovascular Risk Management: Insights from SCOT-HEART 2 Substudy

By MedXY 09/13/2025

A nested substudy from SCOT-HEART 2 reveals coronary CT angiography modestly improves healthy lifestyle adherence, preventive therapy acceptance, and risk factor modification compared to traditional cardiovascular risk scoring in asymptomatic individuals at risk.

Clinical Updates General Surgery Oncology Radiology Specialties

Preoperative versus Postoperative Stereotactic Radiation Therapy for Brain Metastases: Safety, Feasibility, and Efficiency Insights from a Phase 3 Randomized Trial

By MedXY 09/13/2025

A phase 3 randomized trial demonstrates that preoperative stereotactic radiation therapy (SRT) for brain metastases offers comparable safety and reduced treatment duration compared to postoperative SRT, potentially improving patient care logistics.

Oncology Pathology & Lab Medicine Specialties

Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

By MedXY 09/13/2025

Change in circulating tumor DNA (ctDNA) one month after treatment initiation predicts progression-free and overall survival in patients with dMMR/MSI-H metastatic colorectal cancer receiving immune checkpoint inhibitors, offering a potential biomarker for therapeutic decision-making.

Clinical Updates news Oncology Radiology Specialties

Induction vs Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

By MedXY 09/12/2025

This phase 3 trial compares induction-concurrent chemotherapy with concurrent-adjuvant chemotherapy in high-risk N2 to N3 nasopharyngeal carcinoma, finding no significant difference in 3-year progression-free survival while highlighting distinct safety profiles.

Anesthesiology Clinical Updates General Surgery news Specialties

Intercostal Nerve Block: A Viable Alternative to Thoracic Epidural for Pain Control in Lung Surgery

By MedXY 09/12/2025

This randomized trial demonstrates that single-shot intercostal nerve block offers noninferior pain relief compared to thoracic epidural analgesia after thoracoscopic lung resection, with benefits in opioid reduction, mobility, and shorter hospitalization.

AI news Ophthalmology Specialties

Deep Learning Prediction of Retinal Nerve Fiber Layer Thickness as a Novel Risk Biomarker for Glaucoma in Ocular Hypertension

By MedXY 09/12/2025

A novel deep learning model predicted retinal nerve fiber layer thickness from optic disc photos, enabling risk stratification for primary open-angle glaucoma in ocular hypertension patients, with baseline and longitudinal changes strongly correlated with disease conversion.

Clinical Updates news Oncology Specialties

U-BOMB Phase 2 Trial: Promising Activity of Utidelone Plus Bevacizumab in ERBB2-Negative Metastatic Breast Cancer with Active Brain Metastases

By MedXY 09/12/2025

The U-BOMB phase 2 trial demonstrates that the combination of utidelone and bevacizumab shows encouraging efficacy and tolerability in patients with ERBB2-negative metastatic breast cancer and active brain metastases, addressing a critical unmet clinical need.

AI Ophthalmology Specialties

Deep Learning Predicts Glaucoma Risk via Retinal Nerve Fiber Layer Thickness from Ocular Hypertension Photographs

By MedXY 09/12/2025

Deep learning models predicting RNFL thickness from optic disc photographs can identify ocular hypertension patients at higher risk for primary open-angle glaucoma, enhancing early risk assessment and monitoring disease progression.

Cardiology Specialties

Baxdrostat: A Promising New Agent for Managing Uncontrolled and Resistant Hypertension

By MedXY 09/11/2025

Baxdrostat, a novel aldosterone synthase inhibitor, significantly reduces systolic blood pressure in patients with uncontrolled or resistant hypertension, offering a new therapeutic option with a favorable safety profile.

Clinical Updates Oncology Specialties

High-Dose Aumolertinib Demonstrates Promising Efficacy in Untreated EGFR-Mutant NSCLC with Brain Metastases: Insights from the ACHIEVE Phase 2 Trial

By MedXY 09/11/2025

The ACHIEVE Phase 2 trial reveals that high-dose aumolertinib offers significant intracranial and systemic control with a manageable safety profile in patients with untreated EGFR-mutant NSCLC and brain metastases, highlighting its therapeutic potential.